Qualcomm (QCOM) shares are declining in premarket trading as its licensing revenue comes in below expectations; Eli Lilly (LLY) beats adjusted profit estimates but misses them on weight-loss drug ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

In a report released yesterday, Mark Lipacis from Evercore ISI maintained a Hold rating on Qualcomm (QCOM – Research Report), with a price ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Earnings are in focus following the latest quarterly reports from Qualcomm (QCOM), Arm (ARM), Ford (F), Eli Lilly (LLY), Roblox (RBLX), Hershey (HSY), and many more. Eyes are also on Amazon (AMZN), ...

Eli Lilly’s momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling revenue growth, long-term margin expansion, and an ethos driving America’s health focus across ...

Shares of Qualcomm (QCOM) fell in after-hours trading after the semiconductor and equipment giant announced its first-quarter earnings, which exceeded market expectations. The company reported ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast Eli Lilly ...